GlassScriptPhysician profile
Sabah Patel
NPI 1497200687
$904.14
in general payments reported to CMS, 2019-2025
18 companies · $82.76 in 2025
The $82.76 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $401 · 2023: $153 · 2024: $267 · 2025: $82.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $502.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $203.35 | 2022-2024 | Ozempic, Rybelsus |
| Dexcom, INC. | $131.06 | 2023-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $86.92 | 2022-2025 | |
| Abbott Laboratories | $72.75 | 2022-2023 | Freestyle Libre 3 |
| Grt US Holding, INC. | $67.06 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.49 | 2022 | |
| Amneal Pharmaceuticals LLC | $44.74 | 2023-2024 | Unithroid |
| Amgen INC. | $38.50 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.84 | 2022-2023 | Jardiance |
| Recordati_rare_diseases_inc. | $35.44 | 2023 | Signifor Lar, Isturisa |
| Horizon Therapeutics Plc | $21.22 | 2022 | |
| Corcept Therapeutics | $20.29 | 2022 | |
| Jazz Pharmaceuticals INC. | $20.01 | 2022 | |
| Lilly USA, LLC | $18.34 | 2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $16.79 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $15.68 | 2024 | |
| Medtronic, INC. | $12.65 | 2022 | |
| Cequr Corporation | $12.01 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabah Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.